Indeed, bladder tumors with low protein levels of MSH2 have poorer overall survival when treated with CDDP-base therapy, and the CDDP resistance screen suggests that MSH2 is the top one gene candidate based on statistical significance [13]. Here, MSH2 is linked to urinary bladder neoplasm.